Bartsch, Yannic C. http://orcid.org/0000-0002-3844-3056
Wang, Chuangqi
Zohar, Tomer
Fischinger, Stephanie http://orcid.org/0000-0003-2307-3379
Atyeo, Caroline http://orcid.org/0000-0002-7489-0232
Burke, John S. http://orcid.org/0000-0003-1282-8211
Kang, Jaewon http://orcid.org/0000-0003-0846-4611
Edlow, Andrea G.
Fasano, Alessio http://orcid.org/0000-0002-2134-0261
Baden, Lindsey R.
Nilles, Eric J. http://orcid.org/0000-0001-7044-5257
Woolley, Ann E.
Karlson, Elizabeth W.
Hopke, Alex R. http://orcid.org/0000-0003-4860-4121
Irimia, Daniel http://orcid.org/0000-0001-7347-2082
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Ryan, Edward T.
Charles, Richelle C. http://orcid.org/0000-0002-8881-1849
Julg, Boris D.
Lauffenburger, Douglas A. http://orcid.org/0000-0002-0050-989X
Yonker, Lael M.
Alter, Galit http://orcid.org/0000-0002-7680-9215
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (3R37AI080289-11S1, U01CA260476, R01 AI146779)
U.S. Department of Health & Human Services | Centers for Disease Control and Prevention (U01CK0009490)
Bill and Melinda Gates Foundation (Global Health Vaccine Accelerator Platform)
Massachusetts Consortium on Pathogen Readiness Funding Award
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI135995)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5K08HL143183)
Cystic Fibrosis Foundation (YONKER18Q0)
Article History
Received: 4 September 2020
Accepted: 25 January 2021
First Online: 12 February 2021
Competing interests
: G.A. is a founder of Seromyx Systems, a company developing a platform technology that describes the antibody immune response. G.A.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors have declared that no conflicts of interest exist.
Free to read: This content has been made available to all.